Fore Capital’s Bristol-Myers Squibb BMY Stock Holding History

Fore Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-15,000	Closed	-$1M	–	54
2021 Q2	$1M	Buy	+15,000	New	+$978K	0.31%	44
2020 Q1	–	Sell	-40,000	Closed	-$2.57M	–	74
2019 Q4	$2.57M	Hold	40,000	–	–	0.45%	26
2019 Q3	$2.03M	Sell	40,000 -40,000	-50%	-$1.88M	0.12%	25
2019 Q2	$3.63M	Buy	+80,000	New	+$3.73M	0.54%	29

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Fore Capital's BMY Position: Q3 2021 in Review

Fore Capital sold out of Bristol-Myers Squibb (BMY) in Q3 2021, closing a stake of 15,000 shares — an estimated $1M sold.

Fore Capital first reported a position in BMY in Q2 2019 and held it in 4 quarters. The position peaked at $3.63M in Q2 2019. 2,293 funds tracked by Wall St. Rank hold BMY as of Q3 2021.

Fore Capital reported no remaining Bristol-Myers Squibb position as of Q3 2021 after selling out during the quarter.
Fore Capital sold 15,000 Bristol-Myers Squibb shares in Q3 2021, an estimated $1M.
Fore Capital first reported a position in Bristol-Myers Squibb in Q2 2019 and held it in 4 quarters.
Fore Capital's Bristol-Myers Squibb position peaked at $3.63M in Q2 2019.
2,293 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2021.

Based on Fore Capital's 13F filing for Q3 2021, filed 12 Nov 2021.